Effect of intensive insulin therapy on the somatotropic axis of critically ill children.
暂无分享,去创建一个
G. Van den Berghe | R. Baxter | S. Lamberts | I. Vanhorebeek | J. Janssen | M. Gielen | D. Mesotten | M. Brugts | W. Coopmans | E. van Herck
[1] G. Van den Berghe,et al. Glucose dysregulation and neurological injury biomarkers in critically ill children. , 2010, The Journal of clinical endocrinology and metabolism.
[2] D. Chinkes,et al. Intensive insulin therapy improves insulin sensitivity and mitochondrial function in severely burned children* , 2010, Critical care medicine.
[3] M. Rigby,et al. A disparity between physician attitudes and practice regarding hyperglycemia in pediatric intensive care units in the United States: a survey on actual practice habits , 2010, Critical care.
[4] Miet Schetz,et al. Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target? , 2009 .
[5] Stephane Heritier,et al. Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.
[6] Greet Van den Berghe,et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study , 2009, The Lancet.
[7] Kiran B. Hebbar,et al. Neuroendocrine dysfunction in pediatric critical illness* , 2009, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[8] J. L. Messina,et al. Crosstalk between growth hormone and insulin signaling. , 2009, Vitamins and hormones.
[9] Christopher R Palmer,et al. Early insulin therapy in very-low-birth-weight infants. , 2008, The New England journal of medicine.
[10] M. Ranke,et al. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. , 2008, The Journal of clinical endocrinology and metabolism.
[11] G. Van den Berghe,et al. Effect of intensive insulin therapy on insulin sensitivity in the critically ill. , 2007, The Journal of clinical endocrinology and metabolism.
[12] D. Clemmons. IGF-I assays: current assay methodologies and their limitations , 2007, Pituitary.
[13] G. Van den Berghe,et al. Changes within the growth hormone/insulin-like growth factor I/IGF binding protein axis during critical illness. , 2006, Endocrinology and metabolism clinics of North America.
[14] G. Van den Berghe,et al. Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.
[15] A. Dona,et al. Activity of the Growth Hormone/Insulin-like Growth Factor-I Axis in Critically Ill Children , 2005, Journal of pediatric endocrinology & metabolism : JPEM.
[16] J. Frystyk,et al. Residual β-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 Diabetes , 2004 .
[17] G. Van den Berghe,et al. Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. , 2004, The Journal of clinical endocrinology and metabolism.
[18] H. Orskov,et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. , 2003, American journal of physiology. Endocrinology and metabolism.
[19] G. Van den Berghe,et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. , 2002, The Journal of clinical endocrinology and metabolism.
[20] W. Hop,et al. Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. , 2002, The Journal of clinical endocrinology and metabolism.
[21] R. Baxter,et al. Changes in the IGF-IGFBP axis in critical illness. , 2001, Best practice & research. Clinical endocrinology & metabolism.
[22] M Schetz,et al. Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.
[23] M. Fisberg,et al. The role of insulin-like growth factor I, growth hormone, and plasma proteins in surgical outcome of children with congenital heart disease , 2001, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[24] N R Webster,et al. Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.
[25] G. Van den Berghe,et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.
[26] R. Baxter,et al. Thrity-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients , 1998 .
[27] G. Van den Berghe,et al. Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. , 1998, The Journal of clinical endocrinology and metabolism.
[28] R. Ross,et al. The role of IGFs in catabolism. , 1997, Bailliere's clinical endocrinology and metabolism.
[29] B. Tönshoff,et al. Insulin-like growth factors (IGFs) and IGF binding proteins, serum acid-labile subunit and growth hormone binding protein in nephrotic children. , 1997, Kidney international.
[30] C. Hinds,et al. Growth hormone and insulin- like growth factors in critical illness , 1997, Intensive Care Medicine.
[31] M. Tauber,et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM , 1996, Diabetologia.
[32] P. Hindmarsh,et al. An assessment of growth hormone provocation tests. , 1995, Archives of disease in childhood.
[33] J. Wahren,et al. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. , 1994, The Journal of clinical endocrinology and metabolism.
[34] M. Binoux,et al. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. , 1994, The Journal of clinical investigation.
[35] O. Ljungqvist,et al. Development of postoperative insulin resistance is associated with the magnitude of operation. , 1993, The European journal of surgery = Acta chirurgica.
[36] S. Amiel,et al. Suppression of endogenous insulin secretion regulates the rapid rise of insulin‐like growth factor binding protein (IGFBP)‐1 levels following acute hypoglycaemia , 1993, Clinical endocrinology.
[37] R. Baxter,et al. Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.
[38] R. Baxter,et al. Regulation of growth hormone-independent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants. , 1989, The Journal of clinical endocrinology and metabolism.
[39] M. Seppälä,et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. , 1988, The Journal of clinical endocrinology and metabolism.
[40] R. Baxter,et al. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. , 1986, The Journal of clinical investigation.
[41] R. Wolfe,et al. Mechanisms of Insulin Resistance Following Injury , 1982, Annals of surgery.
[42] T. Brown,et al. Fasting plasma glucose in children , 1980, Australian paediatric journal.
[43] R. Baxter,et al. Regulation of hepatic growth hormone receptors by insulin. , 1978, Biochemical and biophysical research communications.
[44] L. Phillips,et al. The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver. , 1976, Endocrinology.